



September 6, 2011

On Friday, September 2, 2011, the Food and Drug Administration (FDA) concluded a five-day inspection of Cetero's Houston bioanalytical laboratory. This event was expected, and was part of the FDA's commitment to re-inspect Cetero-Houston and evaluate its compliance to permit use of this facility for requested re-analysis.

The FDA issued **no Form 483 observations** at the conclusion of its inspection, sending a clear message that Cetero-Houston is operating in full compliance with FDA regulations. It reinforces the unwavering commitment to quality that exists within Cetero, further evidenced by the fact that since September 2010 the FDA has inspected Cetero-Fargo, Cetero-St. Louis, and Cetero-Toronto a combined six times with no Form 483 observations having been issued.

We will continue to keep you informed as we work with the FDA to address and resolve the issues raised in the Untitled Letter of July 26, 2011.

**For more information, please contact:**

April Johnson  
Vice President, Business Relationship Management  
Cetero Research  
Direct Line: 919-468-4214  
Email: [april.johnson@cetero.com](mailto:april.johnson@cetero.com)

Troy W. McCall, Ph.D.  
Chief Executive Officer  
Cetero Research  
Direct Line: 919-674-0280  
Email: [troy.mccall@cetero.com](mailto:troy.mccall@cetero.com)